NCOA2 Antikörper (N-Term)
-
- Target Alle NCOA2 Antikörper anzeigen
- NCOA2 (Nuclear Receptor Coactivator 2 (NCOA2))
-
Bindungsspezifität
- N-Term
-
Reaktivität
- Human, Maus, Ratte, Hund, Kaninchen, Rind (Kuh), Meerschweinchen, Pferd, Schwein
-
Wirt
- Kaninchen
-
Klonalität
- Polyklonal
-
Konjugat
- Dieser NCOA2 Antikörper ist unkonjugiert
-
Applikation
- Western Blotting (WB)
- Sequenz
- MSGMGENTSD PSRAETRKRK ECPDQLGPSP KRNTEKRNRE QENKYIEELA
- Homologie
- Cow: 93%, Dog: 100%, Guinea Pig: 93%, Horse: 100%, Human: 100%, Mouse: 100%, Pig: 100%, Rabbit: 100%, Rat: 100%
- Produktmerkmale
- This is a rabbit polyclonal antibody against NCOA2. It was validated on Western Blot using a cell lysate as a positive control.
- Aufreinigung
- Affinity Purified
- Immunogen
- The immunogen is a synthetic peptide directed towards the N terminal region of human NCOA2
- Top Product
- Discover our top product NCOA2 Primärantikörper
-
-
- Applikationshinweise
- Optimal working dilutions should be determined experimentally by the investigator.
- Kommentare
-
Antigen size: 1464 AA
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Konzentration
- Lot specific
- Buffer
- Liquid. Purified antibody supplied in 1x PBS buffer with 0.09 % (w/v) sodium azide and 2 % sucrose.
- Konservierungsmittel
- Sodium azide
- Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Handhabung
- Avoid repeated freeze-thaw cycles.
- Lagerung
- -20 °C
- Informationen zur Lagerung
- For short term use, store at 2-8°C up to 1 week. For long term storage, store at -20°C in small aliquots to prevent freeze-thaw cycles.
-
-
ETV6-NCOA2: a novel fusion gene in acute leukemia associated with coexpression of T-lymphoid and myeloid markers and frequent NOTCH1 mutations." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 14, Issue 4, pp. 977-83, (2008) (PubMed).
: "
-
ETV6-NCOA2: a novel fusion gene in acute leukemia associated with coexpression of T-lymphoid and myeloid markers and frequent NOTCH1 mutations." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 14, Issue 4, pp. 977-83, (2008) (PubMed).
-
- Target
- NCOA2 (Nuclear Receptor Coactivator 2 (NCOA2))
- Andere Bezeichnung
- NCOA2 (NCOA2 Produkte)
- Synonyme
- GRIP1 antikoerper, KAT13C antikoerper, NCoA-2 antikoerper, SRC2 antikoerper, TIF2 antikoerper, bHLHe75 antikoerper, 9530095N19 antikoerper, D1Ertd433e antikoerper, GRIP-1 antikoerper, Grip1 antikoerper, SRC-2 antikoerper, TIF-2 antikoerper, tif2 antikoerper, wu:fc41a10 antikoerper, wu:fe26a11 antikoerper, Tif2 antikoerper, NCOA2 antikoerper, XTIF2 antikoerper, bhlhe75 antikoerper, grip1 antikoerper, kat13c antikoerper, src2 antikoerper, ncoa2-A antikoerper, nuclear receptor coactivator 2 antikoerper, nuclear receptor coactivator 2 S homeolog antikoerper, NCOA2 antikoerper, Ncoa2 antikoerper, ncoa2 antikoerper, LOC100089041 antikoerper, ncoa2.S antikoerper
- Hintergrund
-
NCOA2 is the transcriptional coactivator for steroid receptors and nuclear receptors. NCOA2 is the coactivator of the steroid binding domain (AF-2) but not of the modulating N-terminal domain (AF-1). NCOA2 is required with NCOA1 to control energy balance
Alias Symbols: GRIP1, KAT13C, MGC138808, NCoA-2, TIF2, SRC2, bHLHe75
Protein Interaction Partner: VDR, PSMB9, PPARG, ESR1, PML, UBC, TP53, TAF9, Pias3, tat, THRB, NR3C1, EP300, NR1I2, RXRA, RARA, CREBBP, AHR, KANK2, MAGEA11, NCOA1, HHV8GK18_gp81, ESR2, PGR, SUMO2, CAD, ATR, HSPA2, CC2D1A, UBR5, TBK1, WDHD1, USO1, STAT6, NCOA3, THRA, CDK4, CCND3, EID1,
Protein Size: 1464 - Molekulargewicht
- 159 kDa
- Gen-ID
- 10499
- NCBI Accession
- NM_006540, NP_006531
- UniProt
- Q15596
- Pathways
- Intracellular Steroid Hormone Receptor Signaling Pathway, Regulation of Intracellular Steroid Hormone Receptor Signaling, Nuclear Hormone Receptor Binding, Regulation of Lipid Metabolism by PPARalpha, Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, CXCR4-mediated Signaling Events, Thromboxane A2 Receptor Signaling
-